Skip to main content
CATALYST PHARMACEUTICALS, INC. logo

CATALYST PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · CPRX ISIN · US14888U1016 LEI · 5299004O0R5XXLA5H544 US Manufacturing
Open in API
Filings indexed 1,130 across all filing types
Latest filing 2026-06-08 Merger & Acquisition
Country US United States of America
Listing US CPRX

About CATALYST PHARMACEUTICALS, INC.

https://catalystpharma.com/

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing prescription drugs for rare diseases. The company is dedicated to improving the lives of patients with underserved medical conditions, particularly in the fields of neurology and epilepsy. Its portfolio includes therapies for rare autoimmune disorders such as Lambert-Eaton myasthenic syndrome (LEMS). The company also markets FYCOMPA (perampanel), a medication used to treat partial-onset seizures.

Recent filings

Filing Released Lang Actions
DEFM14A
Merger & Acquisition
2026-06-08 English
8-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
Report Publication Announcement Classification · 94% confidence The document is a Form 8-K current report that does not itself provide substantive financial data but states that the company issued a press release with its quarterly results, attaching it as Exhibit 99.1. It is primarily announcing the publication of that press release. This fits the definition of a Report Publication Announcement (RPA) rather than the earnings release itself or another filing type.
2026-05-11 English
8-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
M&A Activity Classification · 88% confidence The document is a Form 8-K current report under Item 1.01 "Entry into a Material Definitive Agreement" describing the Agreement and Plan of Merger between Catalyst Pharmaceuticals, Inc. and Angelini Pharma S.p.A., including merger terms, conditions, and related voting agreements. This is a clear announcement of M&A activity (a merger proposal) rather than a full proxy or earnings release. Therefore it falls under M&A Activity (Code: TAR).
2026-05-07 English
SCHEDULE 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)
Major Shareholding Notification
2026-03-26 English
8-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates that the company issued a press release announcing its quarterly and fiscal year-end results and revenue guidance, and the press release is attached as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release. Given the short length (3028 characters) and the nature of the content (announcement of earnings results via press release), this fits the definition of an Earnings Release (ER) rather than a full Interim/Quarterly Report (IR) or Annual Report (10-K). The Form 8-K is commonly used to file earnings releases. Therefore, the appropriate classification is Earnings Release (ER).
2026-02-25 English
10-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
Annual Report FY 2025
2026-02-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.